ADMA Biologics, Inc. (NASDAQ:ADMA) Sees Significant Decrease in Short Interest

ADMA Biologics, Inc. (NASDAQ:ADMA) saw a significant decline in short interest during the month of November. As of November 30th, there was short interest totalling 12,910,000 shares, a decline of 9.3% from the November 15th total of 14,240,000 shares. Based on an average trading volume of 4,970,000 shares, the days-to-cover ratio is currently 2.6 days.

Insider Transactions at ADMA Biologics

In related news, CFO Brad L. Tade sold 15,000 shares of ADMA Biologics stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the completion of the sale, the chief financial officer now directly owns 199,433 shares of the company’s stock, valued at $4,218,007.95. The trade was a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 3.70% of the stock is currently owned by corporate insiders.

Institutional Trading of ADMA Biologics

Institutional investors have recently bought and sold shares of the business. State Street Corp increased its holdings in shares of ADMA Biologics by 61.4% during the third quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company’s stock worth $259,970,000 after purchasing an additional 4,945,063 shares during the period. Lord Abbett & CO. LLC bought a new stake in shares of ADMA Biologics in the third quarter valued at approximately $61,858,000. Bank of Montreal Can acquired a new stake in ADMA Biologics during the second quarter worth approximately $17,886,000. D. E. Shaw & Co. Inc. increased its stake in ADMA Biologics by 26.8% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock worth $76,298,000 after acquiring an additional 1,442,799 shares during the period. Finally, Principal Financial Group Inc. raised its holdings in ADMA Biologics by 785.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company’s stock valued at $23,872,000 after acquiring an additional 1,059,394 shares in the last quarter. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Stock Performance

NASDAQ:ADMA opened at $18.59 on Monday. The stock has a 50 day simple moving average of $19.02 and a 200 day simple moving average of $16.10. The stock has a market cap of $4.39 billion, a P/E ratio of 66.39 and a beta of 0.70. ADMA Biologics has a 1-year low of $3.95 and a 1-year high of $23.64. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The company had revenue of $119.84 million during the quarter, compared to the consensus estimate of $107.25 million. During the same quarter last year, the firm earned $0.01 earnings per share. Research analysts anticipate that ADMA Biologics will post 0.52 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on ADMA. Cantor Fitzgerald reissued an “overweight” rating and issued a $20.00 price target on shares of ADMA Biologics in a report on Friday, September 20th. Raymond James upped their price objective on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research note on Friday, November 8th. Finally, HC Wainwright lifted their price target on ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, November 8th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.